- Home
- NE vs ACAD Comparison
NE vs ACAD Comparison
Compare NE & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NE | ACAD |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.4B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | NE | ACAD |
|---|---|---|
| Price | $45.82 | $22.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 22 |
| Target Price | ★ $37.57 | $29.95 |
| AVG Volume (30 Days) | ★ 2.6M | 1.3M |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | 1.35 | ★ 1.54 |
| Revenue | ★ $3,107,207,000.00 | $1,047,118,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | $7.99 | $11.24 |
| P/E Ratio | $33.94 | ★ $14.29 |
| Revenue Growth | 6.46 | ★ 12.69 |
| 52 Week Low | $17.40 | $13.40 |
| 52 Week High | $46.31 | $28.35 |
Technical Indicators
Market Signals| Indicator | NE | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 79.05 | 30.11 |
| Support Level | $40.69 | $21.51 |
| Resistance Level | $44.17 | $26.23 |
| Average True Range (ATR) | 1.95 | 0.93 |
| MACD | 0.78 | -0.38 |
| Stochastic Oscillator | 96.02 | 9.11 |
Price Performance
Historical ComparisonAbout NE Noble Corporation plc A
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.